The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Bevacizumab plus capecitabine as maintenance treatment after initial treatment with bevacizumab plus XELOX in previously untreated metastatic colorectal cancer: Updated findings from a randomized, multicenter phase III trial.
S. Yalcin
Consultant or Advisory Role - Roche (I,U)
R. Uslu
No relevant relationships to disclose
F. Dane
No relevant relationships to disclose
U. Yilmaz
No relevant relationships to disclose
N. Zengin
No relevant relationships to disclose
E. Buyukunal
No relevant relationships to disclose
S. Buyukberber
No relevant relationships to disclose
C. Camci
No relevant relationships to disclose
O. Sencan
No relevant relationships to disclose
S. Kilickap
No relevant relationships to disclose